Scleroderma Research Grant Program

Peer-Review

The National Scleroderma Foundation is the leading nonprofit supporter of peer-reviewed, scleroderma research to discover the cause, understand the mechanism, and overcome scleroderma forever. Since its inception, the Foundation has committed over $30 million for scleroderma research, which continues as a priority of our mission. Current funding levels are more than  $2 million annually.

Our Peer-Review Research Grant Funding Program has earned a unique place in the field of scleroderma research. It is respected by medical researchers and by government health agencies such as National Institutes of Health (NIH) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The program is administered by the National Scleroderma Foundation’s Board of Directors and staff and is guided by the Foundation’s Peer Research Review Committee. This committee, composed of scleroderma medical experts from around the world, helps determine which proposals will be funded each year by reading, critiquing, and ranking all applications.

The Future of Scleroderma Research

Thanks to recent advances in research and treatment, individuals who have scleroderma as a group can now expect to live longer and more productive lives with increased hope for the future.

A cure for scleroderma, however, remains an elusive goal. Research costs continue to climb. Modern laboratory staff, equipment, and supplies are expensive. Laboratories and clinical research programs must look outside their own facilities for financial support.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of NIH, provides funding for the majority of scleroderma research. Although NIH grants to scleroderma researchers have increased in recent years, scleroderma funding is still a relatively low priority.

The National Scleroderma Foundation has a critically important role as catalyst to fund and to stimulate new research and new ideas. The Foundation is enlisting the support of legislators and other decision makers to establish a higher profile for scleroderma and the needs of individuals with the disease.

The key to all our efforts, to ensure that productive research moves forward, is the continued generosity of our individual and corporate donors.